Skip to main content
NCBI home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 1997 May;34(5):382–390. doi: 10.1136/jmg.34.5.382

Psychological distress in applicants for predictive DNA testing for autosomal dominant, heritable, late onset disorders. The Rotterdam/Leiden Genetics Workgroup.

A C DudokdeWit 1, A Tibben 1, H J Duivenvoorden 1, P G Frets 1, M W Zoeteweij 1, M Losekoot 1, A van Haeringen 1, M F Niermeijer 1, J Passchier 1
PMCID: PMC1050945  PMID: 9152835

Abstract

In a comparative study on the effects of predictive DNA testing for late onset disorders, pre-test psychological distress was assessed in people at risk for Huntington's disease (HD, n = 41), cerebral haemorrhage (HCHWA-D, n = 9), breast and ovarian cancer (HBOC, n = 24), and polyposis coli (FAP, n = 45). Partners, if available, also participated in the study. Distress was measured with the subscales Intrusion and Avoidance of the Impact of Event Scale. People at risk for the neurodegenerative disorders reported more avoidance than those at risk for the cancer syndromes. People at risk for FAP and partners of those at risk for HBOC reported less intrusion than the others at risk and the other partners. Subjects who were more distressed reported more experiences with the disease in close relatives, the disease having a great impact on their lives, having considerations against predictive testing, expecting that being identified as a gene carrier would have adverse effects, and expecting relief after being identified as a non-carrier. Test candidates who expected an increase of personal problems showed higher avoidance, whereas those who could better anticipate future life as a carrier had higher intrusion levels. Generally, subjects with high distress levels are of more concern to the healthcare professional than those with low distress levels. However, high distress may reflect worrying as a mental preparation for the test result, whereas low distress may indicate denial-avoidance behaviour and poor anticipation of the test outcome. In pre-test counselling sessions, this should be acknowledged and addressed.

Full text

PDF
382

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakker E., van Broeckhoven C., Haan J., Voorhoeve E., van Hul W., Levy E., Lieberburg I., Carman M. D., van Ommen G. J., Frangione B. DNA diagnosis for hereditary cerebral hemorrhage with amyloidosis (Dutch type) Am J Hum Genet. 1991 Sep;49(3):518–521. [PMC free article] [PubMed] [Google Scholar]
  2. Bird T. D. Familial Alzheimer's disease. Ann Neurol. 1994 Sep;36(3):335–336. doi: 10.1002/ana.410360303. [DOI] [PubMed] [Google Scholar]
  3. Bloch M., Adam S., Wiggins S., Huggins M., Hayden M. R. Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. Am J Med Genet. 1992 Feb 15;42(4):499–507. doi: 10.1002/ajmg.1320420416. [DOI] [PubMed] [Google Scholar]
  4. Bloch M., Fahy M., Fox S., Hayden M. R. Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet. 1989 Feb;32(2):217–224. doi: 10.1002/ajmg.1320320215. [DOI] [PubMed] [Google Scholar]
  5. Bornebroek M., Haan J., van Buchem M. A., Lanser J. B., de Vries-vd Weerd M. A., Zoeteweij M., Roos R. A. White matter lesions and cognitive deterioration in presymptomatic carriers of the amyloid precursor protein gene codon 693 mutation. Arch Neurol. 1996 Jan;53(1):43–48. doi: 10.1001/archneur.1996.00550010053016. [DOI] [PubMed] [Google Scholar]
  6. Brook J. D., McCurrach M. E., Harley H. G., Buckler A. J., Church D., Aburatani H., Hunter K., Stanton V. P., Thirion J. P., Hudson T. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992 Feb 21;68(4):799–808. doi: 10.1016/0092-8674(92)90154-5. [DOI] [PubMed] [Google Scholar]
  7. Codori A. M., Hanson R., Brandt J. Self-selection in predictive testing for Huntington's disease. Am J Med Genet. 1994 Sep 15;54(3):167–173. doi: 10.1002/ajmg.1320540303. [DOI] [PubMed] [Google Scholar]
  8. Cornelis R. S., Vasen H. F., Meijers-Heijboer H., Ford D., van Vliet M., van Tilborg A. A., Cleton F. J., Klijn J. G., Menko F. H., Meera Khan P. Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. Hum Genet. 1995 May;95(5):539–544. doi: 10.1007/BF00223866. [DOI] [PubMed] [Google Scholar]
  9. Couch F. J., Weber B. L. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat. 1996;8(1):8–18. doi: 10.1002/humu.1380080102. [DOI] [PubMed] [Google Scholar]
  10. Craufurd D., Dodge A., Kerzin-Storrar L., Harris R. Uptake of presymptomatic predictive testing for Huntington's disease. Lancet. 1989 Sep 9;2(8663):603–605. doi: 10.1016/s0140-6736(89)90722-8. [DOI] [PubMed] [Google Scholar]
  11. Craufurd D., Harris R. Predictive testing for Huntington's disease. BMJ. 1989 Apr 1;298(6677):892–892. doi: 10.1136/bmj.298.6677.892-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. De Rooij K. E., De Koning Gans P. A., Skraastad M. I., Belfroid R. D., Vegter-Van Der Vlis M., Roos R. A., Bakker E., Van Ommen G. J., Den Dunnen J. T., Losekoot M. Dynamic mutation in Dutch Huntington's disease patients: increased paternal repeat instability extending to within the normal size range. J Med Genet. 1993 Dec;30(12):996–1002. doi: 10.1136/jmg.30.12.996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Easton D. F., Bishop D. T., Ford D., Crockford G. P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993 Apr;52(4):678–701. [PMC free article] [PubMed] [Google Scholar]
  14. Easton D. F., Ford D., Bishop D. T. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):265–271. [PMC free article] [PubMed] [Google Scholar]
  15. Evers-Kiebooms G., Swerts A., Van Den Berghe H. Partners of Huntington patients: implications of the disease and opinions about predictive testing and prenatal diagnosis. Genet Couns. 1990;1(2):151–159. [PubMed] [Google Scholar]
  16. Fodde R., van der Luijt R., Wijnen J., Tops C., van der Klift H., van Leeuwen-Cornelisse I., Griffioen G., Vasen H., Khan P. M. Eight novel inactivating germ line mutations at the APC gene identified by denaturing gradient gel electrophoresis. Genomics. 1992 Aug;13(4):1162–1168. doi: 10.1016/0888-7543(92)90032-n. [DOI] [PubMed] [Google Scholar]
  17. Ford D., Easton D. F., Bishop D. T., Narod S. A., Goldgar D. E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994 Mar 19;343(8899):692–695. doi: 10.1016/s0140-6736(94)91578-4. [DOI] [PubMed] [Google Scholar]
  18. Groden J., Thliveris A., Samowitz W., Carlson M., Gelbert L., Albertsen H., Joslyn G., Stevens J., Spirio L., Robertson M. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991 Aug 9;66(3):589–600. doi: 10.1016/0092-8674(81)90021-0. [DOI] [PubMed] [Google Scholar]
  19. Haan J., Roos R. A., Briët P. E., Herpers M. J., Luyendijk W., Bots G. T. Hereditary cerebral hemorrhage with amyloidosis--Dutch type. Research-Group Hereditary Cerebral Amyloid-Angiopathy. Clin Neurol Neurosurg. 1989;91(4):285–290. doi: 10.1016/0303-8467(89)90003-6. [DOI] [PubMed] [Google Scholar]
  20. Haltia M., Viitanen M., Sulkava R., Ala-Hurula V., Poyhonen M., Goldfarb L., Brown P., Levy E., Houlden H., Crook R. Chromosome 14-encoded Alzheimer's disease: genetic and clinicopathological description. Ann Neurol. 1994 Sep;36(3):362–367. doi: 10.1002/ana.410360307. [DOI] [PubMed] [Google Scholar]
  21. Harper P. Ethical issues in genetic testing for Huntington's disease: lessons for the study of familial cancers. Dis Markers. 1992 Jul-Aug;10(4):189–228. [PubMed] [Google Scholar]
  22. Hogervorst F. B., Cornelis R. S., Bout M., van Vliet M., Oosterwijk J. C., Olmer R., Bakker B., Klijn J. G., Vasen H. F., Meijers-Heijboer H. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet. 1995 Jun;10(2):208–212. doi: 10.1038/ng0695-208. [DOI] [PubMed] [Google Scholar]
  23. Horowitz M. J. Intrusive and repetitive thoughts after experimental stress. A summary. Arch Gen Psychiatry. 1975 Nov;32(11):1457–1463. doi: 10.1001/archpsyc.1975.01760290125015. [DOI] [PubMed] [Google Scholar]
  24. Horowitz M. J., Wilner N., Kaltreider N., Alvarez W. Signs and symptoms of posttraumatic stress disorder. Arch Gen Psychiatry. 1980 Jan;37(1):85–92. doi: 10.1001/archpsyc.1980.01780140087010. [DOI] [PubMed] [Google Scholar]
  25. Horowitz M., Wilner N., Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979 May;41(3):209–218. doi: 10.1097/00006842-197905000-00004. [DOI] [PubMed] [Google Scholar]
  26. Huggins M., Bloch M., Wiggins S., Adam S., Suchowersky O., Trew M., Klimek M., Greenberg C. R., Eleff M., Thompson L. P. Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet. 1992 Feb 15;42(4):508–515. doi: 10.1002/ajmg.1320420417. [DOI] [PubMed] [Google Scholar]
  27. Kessler S. Forgotten person in the Huntington disease family. Am J Med Genet. 1993 Oct 15;48(3):145–150. doi: 10.1002/ajmg.1320480306. [DOI] [PubMed] [Google Scholar]
  28. Kinzler K. W., Nilbert M. C., Su L. K., Vogelstein B., Bryan T. M., Levy D. B., Smith K. J., Preisinger A. C., Hedge P., McKechnie D. Identification of FAP locus genes from chromosome 5q21. Science. 1991 Aug 9;253(5020):661–665. doi: 10.1126/science.1651562. [DOI] [PubMed] [Google Scholar]
  29. Lerman C., Narod S., Schulman K., Hughes C., Gomez-Caminero A., Bonney G., Gold K., Trock B., Main D., Lynch J. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA. 1996 Jun 26;275(24):1885–1892. [PubMed] [Google Scholar]
  30. Meissen G. J., Mastromauro C. A., Kiely D. K., McNamara D. S., Myers R. H. Understanding the decision to take the predictive test for Huntington disease. Am J Med Genet. 1991 Jun 15;39(4):404–410. doi: 10.1002/ajmg.1320390408. [DOI] [PubMed] [Google Scholar]
  31. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P. A., Harshman K., Tavtigian S., Liu Q., Cochran C., Bennett L. M., Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994 Oct 7;266(5182):66–71. doi: 10.1126/science.7545954. [DOI] [PubMed] [Google Scholar]
  32. Quaid K. A., Morris M. Reluctance to undergo predictive testing: the case of Huntington disease. Am J Med Genet. 1993 Jan 1;45(1):41–45. doi: 10.1002/ajmg.1320450112. [DOI] [PubMed] [Google Scholar]
  33. Quaid K. A., Wesson M. K. Exploration of the effects of predictive testing for Huntington disease on intimate relationships. Am J Med Genet. 1995 May 22;57(1):46–51. doi: 10.1002/ajmg.1320570111. [DOI] [PubMed] [Google Scholar]
  34. Roos R. A., Vegter-van der Vlis M., Hermans J., Elshove H. M., Moll A. C., van de Kamp J. J., Bruyn G. W. Age at onset in Huntington's disease: effect of line of inheritance and patient's sex. J Med Genet. 1991 Aug;28(8):515–519. doi: 10.1136/jmg.28.8.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Schwarzwald J., Solomon Z., Weisenberg M., Mikulincer M. Validation of the Impact of Event Scale for psychological sequelae of combat. J Consult Clin Psychol. 1987 Apr;55(2):251–256. doi: 10.1037//0022-006x.55.2.251. [DOI] [PubMed] [Google Scholar]
  36. Shedler J., Mayman M., Manis M. The illusion of mental health. Am Psychol. 1993 Nov;48(11):1117–1131. doi: 10.1037//0003-066x.48.11.1117. [DOI] [PubMed] [Google Scholar]
  37. Simpson S. A., Besson J., Alexander D., Allan K., Johnston A. W. One hundred requests for predictive testing for Huntington's disease. Clin Genet. 1992 Jun;41(6):326–330. doi: 10.1111/j.1399-0004.1992.tb03407.x. [DOI] [PubMed] [Google Scholar]
  38. Tibben A., Duivenvoorden H. J., Vegter-van der Vlis M., Niermeijer M. F., Frets P. G., van de Kamp J. J., Roos R. A., Rooijmans H. G., Verhage F. Presymptomatic DNA testing for Huntington disease: identifying the need for psychological intervention. Am J Med Genet. 1993 Oct 15;48(3):137–144. doi: 10.1002/ajmg.1320480305. [DOI] [PubMed] [Google Scholar]
  39. Tibben A., Frets P. G., van de Kamp J. J., Niermeijer M. F., Vegter-van der Vlis M., Roos R. A., van Ommen G. J., Duivenvoorden H. J., Verhage F. Presymptomatic DNA-testing for Huntington disease: pretest attitudes and expectations of applicants and their partners in the Dutch program. Am J Med Genet. 1993 May 1;48(1):10–16. doi: 10.1002/ajmg.1320480105. [DOI] [PubMed] [Google Scholar]
  40. Tibben A., Frets P. G., van de Kamp J. J., Niermeijer M. F., Vegtervan der Vlis M., Roos R. A., Rooymans H. G., van Ommen G. J., Verhage F. On attitudes and appreciation 6 months after predictive DNA testing for Huntington disease in the Dutch program. Am J Med Genet. 1993 Jul 15;48(2):103–111. doi: 10.1002/ajmg.1320480209. [DOI] [PubMed] [Google Scholar]
  41. Tibben A., Niermeijer M. F., Roos R. A., Vegter van de Vlis M., Frets P. G., van Ommen G. J., van de Kamp J. J., Verhage F. Understanding the low uptake of presymptomatic DNA testing for Huntington's disease. Lancet. 1992 Dec 5;340(8832):1416–1416. doi: 10.1016/0140-6736(92)92610-r. [DOI] [PubMed] [Google Scholar]
  42. Tibben A., Stevens M., de Wert G. M., Niermeijer M. F., van Duijn C. M., van Swieten J. C. Preparing for presymptomatic DNA testing for early onset Alzheimer's disease/cerebral haemorrhage and hereditary Pick disease. J Med Genet. 1997 Jan;34(1):63–72. doi: 10.1136/jmg.34.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Tibben A., Timman R., Bannink E. C., Duivenvoorden H. J. Three-year follow-up after presymptomatic testing for Huntington's disease in tested individuals and partners. Health Psychol. 1997 Jan;16(1):20–35. doi: 10.1037//0278-6133.16.1.20. [DOI] [PubMed] [Google Scholar]
  44. Watson M., Murday V., Lloyd S., Ponder B., Averill D., Eeles R. Genetic testing in breast/ovarian cancer (BRCA1) families. Lancet. 1995 Aug 26;346(8974):583–583. doi: 10.1016/s0140-6736(95)91424-2. [DOI] [PubMed] [Google Scholar]
  45. Wiggins S., Whyte P., Huggins M., Adam S., Theilmann J., Bloch M., Sheps S. B., Schechter M. T., Hayden M. R. The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med. 1992 Nov 12;327(20):1401–1405. doi: 10.1056/NEJM199211123272001. [DOI] [PubMed] [Google Scholar]
  46. Wijnen J., Vasen H., Khan P. M., Menko F. H., van der Klift H., van Leeuwen C., van den Broek M., van Leeuwen-Cornelisse I., Nagengast F., Meijers-Heijboer A. Seven new mutations in hMSH2, an HNPCC gene, identified by denaturing gradient-gel electrophoresis. Am J Hum Genet. 1995 May;56(5):1060–1066. [PMC free article] [PubMed] [Google Scholar]
  47. Wooster R., Neuhausen S. L., Mangion J., Quirk Y., Ford D., Collins N., Nguyen K., Seal S., Tran T., Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994 Sep 30;265(5181):2088–2090. doi: 10.1126/science.8091231. [DOI] [PubMed] [Google Scholar]
  48. Zilberg N. J., Weiss D. S., Horowitz M. J. Impact of Event Scale: a cross-validation study and some empirical evidence supporting a conceptual model of stress response syndromes. J Consult Clin Psychol. 1982 Jun;50(3):407–414. doi: 10.1037//0022-006x.50.3.407. [DOI] [PubMed] [Google Scholar]
  49. de Rooij K. E., de Koning Gans P. A., Losekoot M., Bakker E., den Dunnen J. T., Vegter-van der Vlis M., Roos R. A., van Ommen G. J. Borderline repeat expansion in Huntington's disease. Lancet. 1993 Dec 11;342(8885):1491–1492. doi: 10.1016/0140-6736(93)92974-x. [DOI] [PubMed] [Google Scholar]
  50. van der Luijt R., Khan P. M., Vasen H., van Leeuwen C., Tops C., Roest P., den Dunnen J., Fodde R. Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test. Genomics. 1994 Mar 1;20(1):1–4. doi: 10.1006/geno.1994.1119. [DOI] [PubMed] [Google Scholar]
  51. van der Steenstraten I. M., Tibben A., Roos R. A., van de Kamp J. J., Niermeijer M. F. Predictive testing for Huntington disease: nonparticipants compared with participants in the Dutch program. Am J Hum Genet. 1994 Oct;55(4):618–625. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES